ArticleEuropean journal of heart failure2020
A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure.
Article in European journal of heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction.Scientific reports · 2022Trial
- Protein biomarkers associated with left bundle branch block in patients with heart failure and reduced ejection fraction.ESC heart failure · 2026Article
- Identifying congestion phenotypes using unsupervised machine learning in acute heart failure.European heart journal. Digital health · 2025Article
- Proteomic Profile of Ischemic Heart Disease in Heart Failure: A Community Study.Mayo Clinic proceedings · 2025Article
- Ferric carboxymaltose for iron deficiency in patients with heart failure: a systematic review and meta-analysis.Future science OA · 2024Review
- Insulin-like Growth Factor-Binding Protein-1 (IGFBP-1) as a Biomarker of Cardiovascular Disease.Biomolecules · 2024Review
- Proteome-wide mendelian randomization investigates potential associations in heart failure and its etiology: emphasis on PCSK9.BMC medical genomics · 2024Article
- Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial.ESC heart failure · 2024Article
- Osteopontin/SPP1: a potential mediator between immune cells and vascular calcification.Frontiers in immunology · 2024Review
- A cluster of blood-based protein biomarkers associated with decreased cerebral blood flow relates to future cardiovascular events in patients with cardiovascular disease.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023Article
- Molecular Mechanisms and Therapeutic Implications of Endothelial Dysfunction in Patients with Heart Failure.International journal of molecular sciences · 2023Review
- Comprehensive analysis of atherosclerotic plaques reveals crucial genes and molecular mechanisms associated with plaque progression and rupture.Frontiers in cardiovascular medicine · 2023Article
- Heart failure: an update from the last years and a look at the near future.ESC heart failure · 2022Review
- Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial.European journal of heart failure · 2022Article
- Pathophysiological pathways in patients with heart failure and atrial fibrillation.Cardiovascular research · 2022Article
- A cluster of blood-based protein biomarkers reflecting coagulation relates to the burden of cerebral small vessel disease.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2022Article
- Comparative study of disease progression for heart failure with different etiologies via time-ordered network analysis.American journal of translational research · 2022Article
- Association between high-mobility group box 2 and subclinical hypertension-mediated organ damage in young adults.Therapeutic advances in chronic disease · 2022Article
- Soluble fibrin monomer complex as a candidate sentinel for adverse events in patients with heart failure.International journal of cardiology. Heart & vasculature · 2021Article
- Finding a Needle in a Haystack: Proteomics in Heart Failure.JACC. Basic to translational science · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 8 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsHeart failure (HF) is frequently caused by an ischaemic event (e.g. myocardial infarction) but might also be caused by a primary disease of the myocardium (cardiomyopathy). In order to identify targeted therapies specific for either ischaemic or non-ischaemic HF, it is important to better understand differences in underlying molecular mechanisms. METHODS AND
resultsWe performed a biological physical protein-protein interaction network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic HF. First, differentially expressed plasma protein biomarkers were identified in 1160 patients enrolled in the BIOSTAT-CHF study, 715 of whom had ischaemic HF and 445 had non-ischaemic HF. Second, we constructed an enriched physical protein-protein interaction network, followed by a pathway over-representation analysis. Finally, we identified key network proteins. Data were validated in an independent HF cohort comprised of 765 ischaemic and 100 non-ischaemic HF patients. We found 21/92 proteins to be up-regulated and 2/92 down-regulated in ischaemic relative to non-ischaemic HF patients. An enriched network of 18 proteins that were specific for ischaemic heart disease yielded six pathways, which are related to inflammation, endothelial dysfunction superoxide production, coagulation, and atherosclerosis. We identified five key network proteins: acid phosphatase 5, epidermal growth factor receptor, insulin-like growth factor binding protein-1, plasminogen activator urokinase receptor, and secreted phosphoprotein 1. Similar results were observed in the independent validation cohort.
conclusionsPathophysiological pathways distinguishing patients with ischaemic HF from those with non-ischaemic HF were related to inflammation, endothelial dysfunction superoxide production, coagulation, and atherosclerosis. The five key pathway proteins identified are potential treatment targets specifically for patients with ischaemic HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.